• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VATALANIB Drug Record

  • Summary
  • Interactions
  • Claims
  • VATALANIB chembl:CHEMBL101253 Antineoplastic

    Alternate Names:

    CGP-79787
    ZK-222584
    K-222584
    PTK787
    BAY-86-5127
    VATALANIB
    NVP-PTK787
    PTK-787

    Drug Info:

    Drug Class Kinase Inhibitors
    FDA Approval not approved
    Drug Class small molecule
    Drug Indications antineoplastic agent
    (4 More Sources)

    Publications:

    Yamamoto et al., 2007, Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity., J. Dermatol.
    Yan D et al., 2017, Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas., Oncogene
  • VATALANIB   CSF1R

    Interaction Score: 0.4

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Macrophage colony stimulating factor receptor inhibitor

    PMIDs:
    28759044


    Sources:
    DTC ChemblInteractions CIViC

  • VATALANIB   FLT1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Vatalanib
    Novel drug target Established target
    Trial Name vatalanib, PTK 787

    PMIDs:
    17584317


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions

  • VATALANIB   FLT4

    Interaction Score: 0.34

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Vatalanib
    Novel drug target Established target
    Trial Name vatalanib, PTK 787

    PMIDs:
    17584317


    Sources:
    DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • VATALANIB   KIT

    Interaction Score: 0.31

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name vatalanib, PTK 787
    Novel drug target Established target
    Trial Name Vatalanib

    PMIDs:
    None found


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions

  • VATALANIB   PDGFRB

    Interaction Score: 0.27

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes
    Notes

    PMIDs:
    None found


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions

  • VATALANIB   KDR

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Trial Name Vatalanib
    Novel drug target Established target

    PMIDs:
    17584317


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TTD

  • VATALANIB   PDGFRA

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Platelet-derived growth factor receptor inhibitor
    Direct Interaction yes
    Trial Name vatalanib, PTK 787

    PMIDs:
    None found


    Sources:
    DTC TdgClinicalTrial ChemblInteractions

  • VATALANIB   STK3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VATALANIB   FRK

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VATALANIB   RPS6KB1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VATALANIB   EGFR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • VATALANIB   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VATALANIB   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MyCancerGenome: VATALANIB

    • Version: 20-Jun-2017

    Alternate Names:
    PTK787 Development Name
    CGP79787 Development Name
    ZK222584 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • TdgClinicalTrial: VATALANIB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class small molecule
    FDA Approval not approved

    Publications:

  • CIViC: VATALANIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yan D et al., 2017, Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas., Oncogene

  • TTD: VATALANIB

    • Version: 2020.06.01

    Alternate Names:
    D0P6DJ TTD Drug ID

    Drug Info:

    Publications:

  • DTC: VATALANIB

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL101253 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TALC: VATALANIB

    • Version: 12-May-2016

    Alternate Names:
    VATALANIB Primary Drug Name
    VATALANIB Drug Generic Name
    PTK787 Drug Synonym

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL101253

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL101253

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21